Volume : 13, Issue : 04, April – 2026
Title:
LEVOTHYROXINE INDUCED DEEP VENOUS THROMBOSIS
Authors :
C. Rakesh kumar*, Jyoshna somasani, Palle Umamaheshwari. P Soma Shekar
Abstract :
Background: Adverse drug reactions (ADRs) are a significant concern in healthcare, contributing to patient morbidity, extended hospital stays, and increased treatment costs. They are particularly prevalent in tertiary care settings due to polypharmacy, complex disease conditions, and the frequent use of high risk medications. Although pharmacovigilance systems are in place, ADRs are still underreported, highlighting the need for improved monitoring and reporting practices.
Objective: The present study was conducted to evaluate the incidence, pattern, causality, severity and preventability of ADRs in a tertiary care teaching hospital, along with their association with demographic and drug related factors.
Methods: A six-month prospective observational study was carried out in a multispecialty tertiary care hospital. ADR data were collected from both inpatient and outpatient departments using standardized reporting forms. The reported ADRs were assessed for causality using WHO-UMC and Naranjo scale. Data were analyzed using descriptive statistics and chi-square tests, considering p<0.05 as statistically significant.
Results: The incidence of ADRs was found to be 15.33%. A higher proportion of ADRs occurs in males (58.69%0 and in patients aged between 31 and 50 years. Most reactions were categorized as probable (98%0 according to both causality assessment scales. The majority of ADRs were mild in nature (93.47%), while a small percentage were moderate (6.52%). Most ADRs were deemed not preventable (98%). The gastrointestinal system was most affected (31.52%), and antibiotics were the leading drug class associated with ADRs. In most instances, discontinuation of the suspected drug resulted in patient improvement.
Conclusion: ADRs are commonly encounters in hospital settings but are generally mild and manageable strengthening pharmacovigilance systems and promoting active involvement of healthcare professionals, especially pharmacists, can enhance ADR detection, reporting, and overall patient safety.
Keywords: Adverse drug reactions, pharmacovigilance, drug safety, causality assessment, severity and preventability.
Cite This Article:
Please cite this article in press C. Rakesh kumar et al., Levothyroxine Induced Deep Venous Thrombosis, Indo Am. J. P. Sci, 2026; 13(04).
REFERENCES:
1. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(6):988–1028.
2. Squizzato A, Gerdes VE, Brandjes DP, Büller HR, Stam J. Thyroid diseases and cerebrovascular disease. Stroke. 2005;36(10):2302–2310.
3. Stuijver DJ, van Zaane B, Romualdi E, Brandjes DP, Gerdes VE, Squizzato A. The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: a systematic review and meta-analysis. Thromb Haemost. 2012;108(6):1077–1088.
4. Danescu LG, Badshah A, Danescu SC, Janjua M, Marandici AM, Matta F, et al. Venous thromboembolism in thyroid disease. Thromb Haemost. 2009;102(5):943–949.
5. Erem C. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Clin Endocrinol (Oxf). 2006;64(3):323–329.
6. Franchini M, Lippi G, Manzato F, Vescovi PP, Targher G. Hemostatic abnormalities in endocrine and metabolic disorders. Eur J Endocrinol. 2010;162(3):439–451.
7. Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464–474.
8. Undas A, Bleński R, Tracz W, Szczeklik A. Thyroid hormone replacement therapy in hypothyroid women: the effect on clotting and fibrinolysis and the response to aspirin. Thromb Haemost. 2004;92(6):1261–1266.
9. Papazafiropoulou A, Papanas N, Nollen M, Maltezos E, Mikhailidis DP. Diabetes mellitus and venous thromboembolism: a review. Curr Vasc Pharmacol. 2009;7(2):190–196.
10. Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AW, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348(15):1435–1441.
11. Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med. 2002;137(11):904–914.
12. Pomp ER, Rosendaal FR, Doggen CJ. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol. 2008;83(2):97–102.
13. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352.
14. Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003;349(13):1227–1235.
15. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291(2):228–238.